Funding Freeze In Forecast For Next FDA Commissioner
This article was originally published in The Tan Sheet
Executive Summary
Commissioner Margaret Hamburg receives a warm farewell at appropriations hearing, but the House subcommittee chair says fiscal 2016 funding likely will be flat. Hamburg’s pitch globalization has required a massive shift in agency thinking and reach fails to sway House subcommittee.
You may also be interested in...
FDA Personnel Growth Could Have Plateaued For Drugs Program
Only a handful of new FTEs are requested in President Obama’s FY 2016 budget request for human drugs activities, suggesting that GDUFA and other related programs may have reached their critical mass of employees for now.
Hamburg, The Atypical Commissioner, Receives Atypically Fond Farewell
Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she leaves the agency in March with high drug approval numbers, initiatives to improve the OTC monograph and switch programs and increased enforcement in the supplement manufacturing arena.
Rare Cancer Development Consortium Moving Toward Target Selection
An upcoming public meeting will include a look at platforms before the first targets are chosen.